Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Q2 Net Loss Jumps on Increased Revenue

NEW YORK, Aug. 8 – Exelixis on Wednesday reported a second-quarter net loss of $23.7 million, or 30 cents per share, compared with $11.0 million, or 16 cents per share, during the comparable period last year despite posting a 54 percent surge in total revenue.

Wall Street had predicted a net loss of 31 cents per share, according to a poll of six brokers conducted by First Call/Thomson Financial.

In a statement, Exelixis attributed the higher loss to research and development fees and milestone payments from collaborations with various pharmaceutical companies. It added that it expects total expenses to continue climbing into the third quarter at a rate of 20 percent to 25 percent higher than second-quarter levels. The company predicted that third-quarter revenue would be 35 percent to 40 percent higher than second-quarter levels.

Revenue for the quarter ended June 30 increased by $3 million to $8.6 million from the second quarter one year ago, Exelixis said.

Expenses for the South San Francisco, Calif.-based company rose by 83 percent during the second quarter 2001 to $33.4 million from $18.3 million year over year.

The company also spent twice as much on R&D during the second quarter 2001 as it did during the same period last year, it said. In a statement, Exelixis said new collaborations, a new drug-discovery facility, and expanded drug-discovery efforts all contributed to higher R&D costs.

Exelixis’ general and administration expenses rose to $4.3 million from $3.6 million during the year-ago period. The company also incurred costs of $6.7 million for acquired in-process research and development. For example, in April, Exelixis acquired Cologne, Germany-based Artemis Pharmaceuticals in a stock-for-stock deal valued at $24 million.

Shares in Exelixis slipped $0.74 to close at $15.86 in Nasdaq trade on Wednesday.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.